IGF1R and non-small cell lung carcinoma: Targeting IGF-1R in NSCLC has in clinical settings been shown to be complicated and both small molecule inhibitors to IGF-1R/InsR as well as monoclonal antibodies towards IGF-1R have in unselected NSCLC patient cohorts failed to demonstrate efficacy and/or been associated with cytotoxicity [14-18, 20, 32].